arrow
M

Michael Schenker

sf. nectarie oncology center
H指数:48
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PP01.56: Final, 6-Year Outcomes with First-Line (1L) Nivolumab Plus Ipilimumab Plus Chemotherapy (N+I+C) in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) from CheckMate 9LA

PP01.56:一线纳武利尤单抗联合伊匹木单抗联合化疗(N+I+C)在晚期非小细胞肺癌(mNSCLC)患者中的最终6年结局——CheckMate 9LA研究

2026-05-070
PRE
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)

CheckMate 9DW研究的通俗总结:纳武利尤单抗联合伊匹木单抗治疗不可切除的肝细胞癌(晚期肝癌)

2026-04-140
PRE
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC

ENTRÉE 肺平台试验子研究1:法拉地利姆单抗联合多西他赛对比多西他赛单药治疗晚期/复发性NSCLC的II期随机疗效与安全性分析

2026-04-080
PRE
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
Nivolumab for Resected Stage III or IV Melanoma at 9 Years

纳武利尤单抗治疗已切除III期或IV期黑色素瘤9年结果

2025-10-015
PRE
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial

CheckMate 901试验中,仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合吉西他滨-顺铂治疗与单独吉西他滨-顺铂治疗的特征分析

2025-05-200
OAAI
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Xevinapant联合avelumab治疗晚期实体瘤,并在晚期非小细胞肺癌中进行剂量扩展:一项开放标签、非随机 Ib 期研究的探索性生物标志物、安全性和有效性分析

2025-05-080
OA
GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population

GAS5 rs145204276 Ins/Del 多态性与罗马尼亚人群结直肠癌易感性相关

2025-03-270
OA
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗:EMPOWER-Lung 1研究五年结局

2025-03-190
OAAI
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial

纳武利尤单抗联合化疗或伊匹木单抗治疗胃癌和食管癌:一项随机III期试验的探索性生物标志物分析

2025-03-070
OA
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC

KEYLYNK-006 III期研究:比较培美曲塞联合奥拉帕利与培美曲塞联合培美曲塞作为转移性非鳞状非小细胞肺癌维持治疗的疗效。

2025-02-013
PRE
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy

Pembrolizumab联合或不维持Olaparib用于转移性鳞状NSCLC,对一线Pembrolizumab加化疗有反应

2025-02-011
OAAI
Clinically Significant BRCA1 and BRCA2 Germline Variants in Breast Cancer-A Single-Center Experience

临床显著性的BRCA1和BRCA2胚系变异在乳腺癌中的研究——一项单中心经验

CANCERS
IF4.4
2024-12-260
OA
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
2024-11-281
PRE
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

在CheckMate 9LA随机试验中,转移性非小细胞肺癌患者一线nivolumab联合ipilimumab进行2周期化疗与单独4周期化疗的五年结果

2024-11-012
OAAI
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW

纳武利尤单抗(NIVO)联合伊匹木单抗(IPI)与化疗(chemo)作为微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)转移性结直肠癌(mCRC)的一线(1L)治疗:来自CheckMate 8HW研究的亚组疗效和扩展安全性分析

2024-09-010
PRE
Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
2024-04-051
PRE